Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 33, 2009, Pages 14016-14021

  Chan, Keith Syson ^a,b   Espinosa, Inigo ^a   Chao, Mark ^a   Wong, David ^c   Ailles, Laurie ^a   Diehn, Max ^a   Gill, Harcharan ^b   Presti Jr , Joseph ^b   Chang, Howard Y ^c   Van De Rijn, Matt ^a   Shortliffe, Linda ^b   Weissman, Irving L ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

Antibody therapy; Bladder cancer; Cancer stem cell; CD44; CD47

Indexed keywords

BETA CATENIN; BMI1 PROTEIN; CD47 ANTIGEN; HERMES ANTIGEN; MONOCLONAL ANTIBODY; STAT3 PROTEIN; TRANSCRIPTION FACTOR GLI1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CELL HETEROGENEITY; CELL ISOLATION; CELL SUBPOPULATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MACROPHAGE; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR CELL; TUMOR XENOGRAFT;

ANIMALS; ANTIGENS, CD44; CELL LINEAGE; HUMANS; KERATIN-20; KERATIN-5; MACROPHAGES; MICE; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; PHAGOCYTOSIS; PROGNOSIS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 69549114870     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0906549106     Document Type: Article

References (39)

1. Heppner GH (1984) Tumor heterogeneity. Cancer Res 44:2259-2265.
2. Kirkels WJ, Pelgrim OE, Debruyne FM, Vooijs GP, Herman CJ (1982) Soft agar culture of human transitional cell carcinoma colonies from urine. Am J Clin Pathol 78:690-694.
3. Lipponen PK, Eskelinen MJ (1992) Cell proliferation of transitional cell bladder cancer determined by PCNA/cyclin immunostaining. A histopathological description. Anticancer Res 12:577-583.
4. Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414:105-111.
5. Polyak K, Hahn WC (2006) Roots and stems: Stem cells in cancer. Nat Med 12:296-300. (Pubitemid 43355075)
6. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983-3988. (Pubitemid 36418143)
7. Ginestier C, et al. (2007) ALDH1 is amarker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1:555-567. (Pubitemid 350056407)
8. Singh SK, et al. (2004) Identification of human brain tumour initiating cells. Nature 432:396-401. (Pubitemid 39551674)
9. Ricci-Vitiani L, et al. (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445:111-115. (Pubitemid 46067311)
10. O'Brien CA, Pollett A, Gallinger S, Dick JE (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445:106-110. (Pubitemid 46067310)
11. Dalerba P, et al. (2007) Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 104:10158-10163. (Pubitemid 47175279)
12. Prince ME, et al. (2007) Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 104:973-978.
13. Li C, et al. (2007) Identification of pancreatic cancer stem cells. Cancer Res 67:1030-1037. (Pubitemid 46270758)
14. Patrawala L, et al. (2006) Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 25:1696-1708.
15. Schatton T, et al. (2008) Identification of cells initiating human melanomas. Nature 451:345-349.
16. Kelly PN, Dakic A, Adams JM, Nutt SL, Strasser A (2007) Tumor growth need not be driven by rare cancer stem cells. Science 317:337.
17. Quintana E, et al. (2008) Efficient tumour formation by single human melanoma cells. Nature 456:593-598.
18. Bao S, et al. (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756-760. (Pubitemid 44949604)
19. Diehn M, et al. (2009) Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458:780-783.
20. Li X, et al. (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100:672-679.
21. Dinney CP, et al. (2004) Focus on bladder cancer. Cancer Cell 6:111-116.
22. Wu XR (2005) Urothelial tumorigenesis: A tale of divergent pathways. Nature Reviews Cancer 5:713-725.
23. Borden LS, Jr., Clark PE, Hall MC (2004) Bladder cancer. Current Opinion in Oncology16: 257-262.
24. Goldman JP, et al. (1998) Enhanced human cell engraftment in mice deficient in RAG2 and the common cytokine receptor gamma chain. Br J Haematol 103:335-342.
25. Hochedlinger K, Yamada Y, Beard C, Jaenisch R (2005) Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell 121:465-477. (Pubitemid 40692305)
26. Chan KS, et al. (2004) Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J Clin Invest 114:720-728.
27. Reya T, et al. (2003) A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 423:409-414. (Pubitemid 36626987)
28. Park IK, et al. (2003) Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 423:302-305.
29. Niwa H, Burdon T, Chambers I, Smith A (1998) Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3. Genes Dev 12:2048-2060.
30. Chambers I, et al. (2003) Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell 113:643-655. (Pubitemid 36694189)
31. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C (2006) Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 24:778-789. (Pubitemid 46622045)
32. Dyrskjot L, et al. (2004) Gene expression in the urinary bladder: A common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 64:4040-4048. (Pubitemid 38697320)
33. Barclay AN, Brown MH (2006) The SIRP family of receptors and immune regulation. Nature Reviews Immunology 6:457-464.
34. Shmelkov SV, et al. (2008) CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest 118:2111-2120.
35. Honeth G, et al. (2008) The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Research 10:R53.
36. Prehn RT (1970) Analysis of antigenic heterogeneity within individual 3-methylcholanthrene- induced mouse sarcomas. J Natl Cancer Inst 45:1039-1045.
37. Fondrevelle ME, et al. (2009) The expression of Twist has an impact on survival in human bladder cancer and is influenced by the smoking status. Urologic Oncology 27:268-276.
38. Nimmerjahn F, Ravetch JV (2007) Antibodies, Fc receptors and cancer. Curr Opin Immunol 19:239-245.
39. Marinelli RJ, et al. (2008) The Stanford Tissue Microarray Database. Nucleic Acids Res 36:D871-877.